Department of Critical Care Medicine and Hospital Infection Prevention and Control, Shenzhen Second People's Hospital, Shenzhen, 518035, China.
Department of Critical Care Medicine, First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China.
Chin J Traumatol. 2022 Jan;25(1):17-24. doi: 10.1016/j.cjtee.2021.11.001. Epub 2021 Nov 15.
COVID-19 is also referred to as a typical viral septic pulmonary infection by 2019-nCoV. However, little is known regarding its characteristics in terms of systemic inflammation and organ injury, especially compared with classical bacterial sepsis. This article aims to investigate the clinical characteristics and prognosis between COVID-19-associated sepsis and classic bacterial-induced sepsis.
In this retrospective cohort study, septic patients with COVID-19 in the intensive care unit (ICU) of a government-designed therapy center in Shenzhen, China between January 14, 2020 and March 10, 2020, and septic patients induced by carbapenem-resistant klebsiella pneumonia (CrKP) admitted to the ICU of the Second People's Hospital of Shenzhen, China between January 1, 2014 and October 30, 2019 were enrolled. Demographic and clinical parameters including comorbidities, critical illness scores, treatment, and laboratory data, as well as prognosis were compared between the two groups. Risk factors for mortality and survival rate were analyzed using multivariable logistic regression and survival curve, respectively.
A total of 107 patients with COVID-19 and 63 patients with CrKP were enrolled. A direct comparison between the two groups demonstrated more serious degrees of primary lung injury following 2019-nCoV infection (indicated by lower PaO/FiO), but milder systemic inflammatory response, lower sequential organ failure assessment score and better functions of the organs like heart, liver, kidney, coagulation, and circulation. However, the acquired immunosuppression presented in COVID-19 patients was more severe, which presented as lower lymphocyte counts (0.8×10/L vs. 0.9×10/L). Moreover, the proportion of COVID-19 patients treated with corticosteroid therapy and extracorporeal membrane oxygenation was larger compared with CrKP patients (78.5% vs. 38.1% and 6.5% vs. 0, respectively) who required less invasive mechanical ventilation (31.6% vs. 54.0%). The incidence of hospitalized mortality and length of ICU stay and total hospital stay were also lower or shorter in viral sepsis (12.1% vs. 39.7%, 6.5 days vs. 23.0 days and 21.0 days vs. 33.0 days, respectively) (all p < 0.001). Similar results were obtained after being adjusted by age, gender, comorbidity and PaO2/FiO2. Lymphocytopenia and high acute physiology and chronic health evaluation II scores were common risk factors for in-hospital death. While the death cases of COVID-19 sepsis mostly occurred at the later stages of patients' hospital stay.
Critical COVID-19 shares clinical characteristics with classical bacterial sepsis, but the degree of systemic inflammatory response, secondary organ damage and mortality rate are less severe. However, following 2019-nCoV infection, the level of immunosuppression may be increased and thus induce in more death at the later stage of patients' hospitalstay.
2019 年新型冠状病毒(2019-nCoV)引起的新型冠状病毒肺炎(COVID-19)也被称为典型病毒性脓毒症性肺炎。然而,与经典的细菌性败血症相比,人们对其全身炎症和器官损伤特征知之甚少。本文旨在探讨 COVID-19 相关性败血症与经典细菌诱导性败血症的临床特征和预后。
本回顾性队列研究纳入了 2020 年 1 月 14 日至 3 月 10 日期间,在中国深圳市政府设计的治疗中心重症监护病房(ICU)中因 COVID-19 而发生败血症的患者,以及 2014 年 1 月 1 日至 2019 年 10 月 30 日期间,在中国深圳市第二人民医院 ICU 中因耐碳青霉烯类肺炎克雷伯菌(CrKP)而发生败血症的患者。比较了两组患者的人口统计学和临床参数,包括合并症、危重病评分、治疗和实验室数据以及预后。使用多变量逻辑回归和生存曲线分析死亡率和生存率的危险因素。
共纳入了 107 例 COVID-19 患者和 63 例 CrKP 患者。对两组患者进行直接比较,发现 2019-nCoV 感染后原发性肺损伤程度更严重(以 PaO/FiO 比值较低表示),但全身炎症反应较轻,序贯器官衰竭评估评分较低,心、肝、肾、凝血和循环等器官功能较好。然而,COVID-19 患者出现的获得性免疫抑制更为严重,表现为淋巴细胞计数较低(0.8×10/L 比 0.9×10/L)。此外,与 CrKP 患者相比,COVID-19 患者接受皮质类固醇治疗和体外膜氧合的比例更大(分别为 78.5%比 38.1%和 6.5%比 0,需要接受有创机械通气的比例较低(分别为 31.6%比 54.0%)。病毒败血症患者的住院死亡率、ICU 住院时间和总住院时间也较低或较短(分别为 12.1%比 39.7%、6.5 天比 23.0 天和 21.0 天比 33.0 天,均 p<0.001)。在调整年龄、性别、合并症和 PaO2/FiO2 后,也得到了类似的结果。淋巴细胞减少和高急性生理学和慢性健康评估 II 评分是院内死亡的常见危险因素。然而,COVID-19 败血症患者的死亡病例大多发生在住院后期。
严重的 COVID-19 与经典的细菌性败血症具有相似的临床特征,但全身炎症反应、继发性器官损伤和死亡率的程度较轻。然而,在 2019-nCoV 感染后,免疫抑制水平可能会增加,从而导致患者住院后期的死亡风险增加。